Here, female High Drinking in the Dark (HDID) mice were stereotaxically injected with 0.5uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into the NAc. A Drinking in the Dark (DID) experiment lasting 6 weeks was carried out with 2 fluid groups (water or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were serially treated with vehicle prior to DID during week 1 to establish baseline drinking, CNO (1mg/kg) during weeks 2-5 to measure the effects of chronic treatment, and then mice were treated with vehicle again during week 6 to determine if there were any lasting effects of chronic CNO treatment. This gene set comprises 1,473 genes that were differentially expressed in the nucleus accumbens of ethanol drinking HDID mice treated with vehicle as compared to the water drinking and vehicle treated control group.
Authors:
Darya Y. Pozhidayeva, Sean P. Farris, Calla M. Goeke, Evan J. Firsick, Kayla G. Townsley, Marina Guizzetti, and Angela R. Ozburn
Here, female High Drinking in the Dark (HDID) mice were stereotaxically injected with 0.5uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into the NAc. A Drinking in the Dark (DID) experiment lasting 6 weeks was carried out with 2 fluid groups (water or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were serially treated with vehicle prior to DID during week 1 to establish baseline drinking, CNO (1mg/kg) during weeks 2-5 to measure the effects of chronic treatment, and then mice were treated with vehicle again during week 6 to determine if there were any lasting effects of chronic CNO treatment. This gene set comprises 688 genes that were uniquely differentially expressed in the nucleus accumbens of only ethanol drinking HDID mice treated with vehicle as compared to the water drinking and vehicle treated control group.
Authors:
Darya Y. Pozhidayeva, Sean P. Farris, Calla M. Goeke, Evan J. Firsick, Kayla G. Townsley, Marina Guizzetti, and Angela R. Ozburn
GWAS: pulmonary function measurement, forced expiratory volume
Description:
List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Pulmonary function. The EFO term pulmonary function measurement, forced expiratory volume was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.
Authors:
M Soler Artigas, DW Loth, LV Wain, SA Gharib, M Obeidat, W Tang, G Zhai, JH Zhao, AV Smith, JE Huffman, E Albrecht, CM Jackson, DM Evans, G Cadby, M Fornage, A Manichaikul, LM Lopez, T Johnson, MC Aldrich, T Aspelund, I Barroso, H Campbell, PA Cassano, DJ Couper, G Eiriksdottir, N Franceschini, M Garcia, C Gieger, GK Gislason, I Grkovic, CJ Hammond, DB Hancock, TB Harris, A Ramasamy, SR Heckbert, M Heliövaara, G Homuth, PG Hysi, AL James, S Jankovic, BR Joubert, S Karrasch, N Klopp, B Koch, SB Kritchevsky, LJ Launer, Y Liu, LR Loehr, K Lohman, RJ Loos, T Lumley, KA Al Balushi, WQ Ang, RG Barr, J Beilby, JD Blakey, M Boban, V Boraska, J Brisman, JR Britton, GG Brusselle, C Cooper, I Curjuric, S Dahgam, IJ Deary, S Ebrahim, M Eijgelsheim, C Francks, D Gaysina, R Granell, X Gu, JL Hankinson, R Hardy, SE Harris, J Henderson, A Henry, AD Hingorani, A Hofman, PG Holt, J Hui, ML Hunter, M Imboden, KA Jameson, SM Kerr, I Kolcic, F Kronenberg, JZ Liu, J Marchini, T McKeever, AD Morris, AC Olin, DJ Porteous, DS Postma, SS Rich, SM Ring, F Rivadeneira, T Rochat, AA Sayer, I Sayers, PD Sly, GD Smith, A Sood, JM Starr, AG Uitterlinden, JM Vonk, SG Wannamethee, PH Whincup, C Wijmenga, OD Williams, A Wong, M Mangino, KD Marciante, WL McArdle, B Meibohm, AC Morrison, KE North, E Omenaas, LJ Palmer, KH Pietiläinen, I Pin, O Pola Sbreve Ek, A Pouta, BM Psaty, AL Hartikainen, T Rantanen, S Ripatti, JI Rotter, I Rudan, AR Rudnicka, H Schulz, SY Shin, TD Spector, I Surakka, V Vitart, H Völzke, NJ Wareham, NM Warrington, HE Wichmann, SH Wild, JB Wilk, M Wjst, AF Wright, L Zgaga, T Zemunik, CE Pennell, F Nyberg, D Kuh, JW Holloway, HM Boezen, DA Lawlor, RW Morris, N Probst-Hensch, J Kaprio, JF Wilson, C Hayward, M Kähönen, J Heinrich, AW Musk, DL Jarvis, S Gläser, MR Järvelin, BH Ch Stricker, P Elliott, GT O'Connor, DP Strachan, SJ London, IP Hall, V Gudnason, MD Tobin
GWAS: pulmonary function measurement, FEV/FEC ratio
Description:
List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Pulmonary function. The EFO term pulmonary function measurement, FEV/FEC ratio was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.
Authors:
M Soler Artigas, DW Loth, LV Wain, SA Gharib, M Obeidat, W Tang, G Zhai, JH Zhao, AV Smith, JE Huffman, E Albrecht, CM Jackson, DM Evans, G Cadby, M Fornage, A Manichaikul, LM Lopez, T Johnson, MC Aldrich, T Aspelund, I Barroso, H Campbell, PA Cassano, DJ Couper, G Eiriksdottir, N Franceschini, M Garcia, C Gieger, GK Gislason, I Grkovic, CJ Hammond, DB Hancock, TB Harris, A Ramasamy, SR Heckbert, M Heliövaara, G Homuth, PG Hysi, AL James, S Jankovic, BR Joubert, S Karrasch, N Klopp, B Koch, SB Kritchevsky, LJ Launer, Y Liu, LR Loehr, K Lohman, RJ Loos, T Lumley, KA Al Balushi, WQ Ang, RG Barr, J Beilby, JD Blakey, M Boban, V Boraska, J Brisman, JR Britton, GG Brusselle, C Cooper, I Curjuric, S Dahgam, IJ Deary, S Ebrahim, M Eijgelsheim, C Francks, D Gaysina, R Granell, X Gu, JL Hankinson, R Hardy, SE Harris, J Henderson, A Henry, AD Hingorani, A Hofman, PG Holt, J Hui, ML Hunter, M Imboden, KA Jameson, SM Kerr, I Kolcic, F Kronenberg, JZ Liu, J Marchini, T McKeever, AD Morris, AC Olin, DJ Porteous, DS Postma, SS Rich, SM Ring, F Rivadeneira, T Rochat, AA Sayer, I Sayers, PD Sly, GD Smith, A Sood, JM Starr, AG Uitterlinden, JM Vonk, SG Wannamethee, PH Whincup, C Wijmenga, OD Williams, A Wong, M Mangino, KD Marciante, WL McArdle, B Meibohm, AC Morrison, KE North, E Omenaas, LJ Palmer, KH Pietiläinen, I Pin, O Pola Sbreve Ek, A Pouta, BM Psaty, AL Hartikainen, T Rantanen, S Ripatti, JI Rotter, I Rudan, AR Rudnicka, H Schulz, SY Shin, TD Spector, I Surakka, V Vitart, H Völzke, NJ Wareham, NM Warrington, HE Wichmann, SH Wild, JB Wilk, M Wjst, AF Wright, L Zgaga, T Zemunik, CE Pennell, F Nyberg, D Kuh, JW Holloway, HM Boezen, DA Lawlor, RW Morris, N Probst-Hensch, J Kaprio, JF Wilson, C Hayward, M Kähönen, J Heinrich, AW Musk, DL Jarvis, S Gläser, MR Järvelin, BH Ch Stricker, P Elliott, GT O'Connor, DP Strachan, SJ London, IP Hall, V Gudnason, MD Tobin
Here, female High Drinking in the Dark (HDID) mice were stereotaxically injected with 0.5uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into the NAc. A Drinking in the Dark (DID) experiment lasting 6 weeks was carried out with 2 fluid groups (water or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were serially treated with vehicle prior to DID during week 1 to establish baseline drinking, CNO (1mg/kg) during weeks 2-5 to measure the effects of chronic treatment, and then mice were treated with vehicle again during week 6 to determine if there were any lasting effects of chronic CNO treatment. This gene set comprises 1,157 genes that were differentially expressed in water drinking HDID mice treated with CNO as compared to the water drinking and vehicle treated control group (H2O(CNO) vs H2O(VEH)).
Authors:
Darya Y. Pozhidayeva, Sean P. Farris, Calla M. Goeke, Evan J. Firsick, Kayla G. Townsley, Marina Guizzetti, and Angela R. Ozburn
Here, female High Drinking in the Dark (HDID) mice were stereotaxically injected with 0.5uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into the NAc. A Drinking in the Dark (DID) experiment lasting 6 weeks was carried out with 2 fluid groups (water or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were serially treated with vehicle prior to DID during week 1 to establish baseline drinking, CNO (1mg/kg) during weeks 2-5 to measure the effects of chronic treatment, and then mice were treated with vehicle again during week 6 to determine if there were any lasting effects of chronic CNO treatment. This gene set comprises 2,377 genes that were differentially expressed in the nucleus accumbens of ethanol drinking HDID mice treated with CNO as compared to the water drinking and vehicle treated control group.
Authors:
Darya Y. Pozhidayeva, Sean P. Farris, Calla M. Goeke, Evan J. Firsick, Kayla G. Townsley, Marina Guizzetti, and Angela R. Ozburn
Here, female High Drinking in the Dark (HDID) mice were stereotaxically injected with 0.5uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into the NAc. A Drinking in the Dark (DID) experiment lasting 6 weeks was carried out with 2 fluid groups (water or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were serially treated with vehicle prior to DID during week 1 to establish baseline drinking, CNO (1mg/kg) during weeks 2-5 to measure the effects of chronic treatment, and then mice were treated with vehicle again during week 6 to determine if there were any lasting effects of chronic CNO treatment. This gene set comprises 612 genes that were uniquely differentially expressed in the nucleus accumbens of only H2O drinking HDID mice treated with CNO as compared to the water drinking and vehicle treated control group.
Authors:
Darya Y. Pozhidayeva, Sean P. Farris, Calla M. Goeke, Evan J. Firsick, Kayla G. Townsley, Marina Guizzetti, and Angela R. Ozburn
Data from GEO GSE194368 and analyzed using GEO2R, only top gene shown. Authors identified transcriptional adaptations of GR signaling in the amygdala of humans with OUD. Thus, GRs, their coregulators and downstream systems may represent viable therapeutic targets to treat the “stress side” of OUD.
Authors:
Stephanie A Carmack, Janaina C M Vendruscolo, M Adrienne McGinn, Jorge Miranda-Barrientos, Vez Repunte-Canonigo, Gabriel D Bosse, Daniele Mercatelli, Federico M Giorgi, Yu Fu, Anthony J Hinrich, Francine M Jodelka, Karen Ling, Robert O Messing, Randall T Peterson, Frank Rigo, Scott Edwards, Pietro P Sanna, Marisela Morales, Michelle L Hastings, George F Koob, Leandro F Vendruscolo
Positional candidate genes for TAILCLIP_LAT_SEC in BXD RI Females & Males on Chr1
Description:
Position candidates for TAILCLIP_LAT_SEC measured in BXD RI Females & Males. TAILCLIP_LAT_SEC measures Mechanical Nociception - Tail Clip Test under the domain Pain. The QTL found was a Suggestive QTL and spans 92 Mb to 98 Mb.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Hippocampus Gene Expression Correlates for TAILCLIP_LAT_SEC measured in BXD RI Females & Males obtained using GeneNetwork Hippocampus Consortium M430v2 (Jun06) RMA. The TAILCLIP_LAT_SEC measures Mechanical Nociception - Tail Clip Test under the domain Pain. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Whole Brain Gene Expression Correlates for ACTI_DIFF_20 measured in BXD RI Females obtained using INIA Brain mRNA M430 (Jun06) RMA. The ACTI_DIFF_20 measures Difference in distance traveled (cm) during the first last min (saline-ethanol) under the domain Ethanol. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Neocortex Gene Expression Correlates for COCA_TEST_VEHICLE measured in BXD RI Males obtained using GeneNetwork Neocortex ILM6v1.1 (Feb08) RankInv. The COCA_TEST_VEHICLE measures Cocaine CPP - Time (s) in saline paired compartment a under the domain Cocaine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
cocaine related behavior 1 (Cocrb1) spans 79.870166 - 121.405905 Mbp (NCBI Build 37) on Chr 1. Obtained from MGI (http://www.informatics.jax.org) by searching for QTLs containing the keyword .
QTL for METH responses for body temperature on Chr1 at D1Ncvs75 (79.87 Mbp , Build 37)
Description:
METH responses for body temperature spans 54.87 - 104.87 Mbp (NCBI Build 37) on Chr1. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for chronic alcohol withdrawal severity on Chr1 at D1Mit46 (83.89 Mbp , Build 37)
Description:
chronic alcohol withdrawal severity spans 58.89 - 108.89 Mbp (NCBI Build 37) on Chr1. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
Authors:
Bergeson SE, Kyle Warren R, Crabbe JC, Metten P, Gene Erwin V, Belknap JK
QTL for METH responses for home cage activity on Chr1 at D1Ncvs41 (101.77 Mbp , Build 37)
Description:
METH responses for home cage activity spans 76.77 - 126.77 Mbp (NCBI Build 37) on Chr1. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
Genes associated with Homo sapiens that interact with the MeSH term 'Arsenic' (D001151). Incorporates data from 87 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term 'Fluorouracil' (D005472). Incorporates data from 99 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term 'Dexamethasone' (D003907). Incorporates data from 14 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term 'N-acetyl-4-benzoquinoneimine' (C028473). Incorporates data from 14 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term '(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine' (C516138). Incorporates data from 3 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term 'Thimerosal' (D013849). Incorporates data from 20 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
Genes associated with Homo sapiens that interact with the MeSH term 'vorinostat' (C111237). Incorporates data from 13 publications curated by the Comparative Toxicogenomics Database (CTD). ODE Gene scores represent number of supporting publications per gene.
GeneWeaver